



NDA 20-822/S-019

NDA 21-046/S-003

Forest Laboratories, Inc.
Attention: Tracey Varner
Manager, Regulatory Affairs
Harborside Financial Center
Plaza Three, Suite 602
Jersey City, NJ 07311

Dear Ms. Varner:

Please refer to your supplemental new drug applications dated September 30, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Celexa (citalopram hydrobromide) 10 mg, 20 mg and 40 mg Tablets (20-822) and 10 mg/5 ml Oral Solution (21-046).

We additionally acknowledge receipt of your amendment dated November 8, 2002.

These "Changes Being Effected" supplements provide for revisions to the **ADVERSE REACTIONS-Other Events Observed During the Postmarketing Evaluation of Celexa (citalopram HBr)** section of prescriber labeling in order to make it more consistent with the Lexapro (escitalopram oxalate) labeling, NDA 21-323.

We have completed the review of these supplemental applications, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted September 30, 2002/Label Code 13940-14), which incorporates the revisions listed. Accordingly, these supplemental applications are approved effective on the date of this letter.

Labeling changes of the kind which you have proposed under the above supplemental application are permitted by section 314.70(c) of the regulations to be instituted prior to approval of the supplement. It is understood that the changes, described in the above NDA supplements, have been made.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Mr. Paul David, R.Ph., Senior Regulatory Project Manager, at (301) 594-5530.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Russell Katz
11/19/02 09:12:46 AM